BillionToOne
Valuation each multiple against its own 5-year range
Vs. peers Diagnostics & Research
| Company | Market cap | P/E (TTM)i | P/Bi | Div yieldi |
|---|---|---|---|---|
| BillionToOne (BLLN) | 4.30B | 93.18 | 7.58 | 0.00% |
| Thermo Fisher Scientific (TMO) | 248.08B | 35.31 | 4.53 | 0.27% |
| Danaher (DHR) | 155.03B | 36.12 | 2.89 | 0.69% |
| IDEXX Laboratories Inc (IDXX) | 53.28B | 45.57 | 28.50 | 0.00% |
| Agilent Technologies (A) | 48.04B | 33.61 | 6.52 | 0.59% |
| Waters (WAT) | 43.29B | 184.29 | 2.83 | 0.00% |
Other StockVane-tracked companies in the same industry.
Morningstar
Trading 16.5% below Morningstar's fair value estimate.
Fair value
BillionToOne Inc earns a 3-star quantitative star rating, indicating our belief that this share class is a balanced choice, but prudent investors should consider looking elsewhere. The stock currently trades at a price consistent with our quantitative fair value estimate, which has a high uncertainty rating.
The firm's lack of profitability weakens our fair value estimate. Companies with low profitability are often less resilient in recessions and are likely to generate weaker future cash flows for shareholders. Reflecting the firm's profitability is its sales yield of 18.1%, which sits in the bottom 20% globally. This company's inability to generate significant sales growth without meaningful capital investment is a challenge, which contributes to our balanced fair value estimate.
The firm's valuation metrics are an additional cause for concern. A company's valuation metrics provide insights into the market's expectations for its future growth and profitability. The firm's book value yield of 10.4%, for example, lies in the bottom 10% compared with global peers. The market value of this company's shares looks expensive relative to the book (accounting) value of equity, which further promotes our neutral price/fair value ratio.
Economic moat
This company lacks a competitive advantage, receiving a quantitative economic moat rating of none. Additionally, the firm's moderate financial health score suggests it is acceptably positioned against adverse economic circumstances.
By Quantitative Equity Report
Quote time 2026-11-20 20:01:12 · For reference only, not investment advice and not tailored to your situation.
BillionToOne discussion 0 comments